Drug Discovery via Human-Derived Stem Cell Organoids

Area of Science:

• Gastroenterology and Hepatology
• Genetics and Genomics
• Translational Medicine

Background:

• Traditional cell lines and animal models have limitations in accurately reflecting human intestinal disease complexity and predicting drug efficacy.
• Genetically determined intestinal diseases often require specific microenvironments not replicated by standard cell cultures.
• Animal models frequently fail to fully recapitulate human intestinal pathologies and drug responses.

Approach:

• Utilizing patient-derived stem cell organoids as a novel and effective platform for modeling intestinal diseases.
• Employing clustered regularly interspaced short palindromic repeats/CRISPR-associated protein-9 (CRISPR-Cas9) genome editing for precise genetic modification in organoids.
• Investigating the application of organoids in understanding disease pathogenesis, evaluating drug potency and toxicity, and enabling precision medicine.

Key Points:

• Patient-derived organoids provide a more accurate in vitro model for studying inherited intestinal diseases.
• CRISPR-Cas9 technology allows precise genetic manipulation within organoids to identify disease-related genes.
• Organoids facilitate better evaluation of drug candidate potency and toxicity compared to traditional models.
• These models are applicable to a range of diseases, including cancer and infectious diseases.

Conclusions:

• Patient-derived organoids represent a significant advancement in modeling human intestinal diseases and developing targeted therapies.
• The integration of organoid technology with genome editing tools enhances research capabilities for disease pathogenesis and drug discovery.
• Organoids offer a versatile platform for applications spanning basic research, drug screening, and precision medicine.